curriculum dell'attività didattica e scientifica ... 2019.pdfpensionamento del mentore, la...
TRANSCRIPT
Prof. Claudio Ferri
Curriculum
dell'attività didattica e scientifica (corredato di dati biografici ed
attività assistenziale)
2
2019
Dati biografici
Eta':
nato a Roma il 20.6.1957.
Stato civile:
Sposato con due figli.
Residenza:
Via Ticino 5/A, 00198 Roma.
Domicilio:
Viale San Salvatore – Edificio Delta 6 - 67100 L’Aquila
Qualifica attuale:
Accademica: Professore Ordinario in Medicina Interna
l’Università dell’Aquila
Assistenziale: Direttore U.O.C. Medicina Interna e Nefrologia
Ospedale San Salvatore – L’Aquila
Afferenza attuale:
Accademica: Università dell’Aquila – Dipartimento di Medicina
Clinica, Sanità Pubblica, Scienza della Vita e dell’Ambiente (MeSVA)
Assistenziale: Ospedale San Salvatore (L’Aquila) – U.O.C. Medicina
Interna e Nefrologia
3
Studi:
Maturita' scientifica (voto 60/60) – Liceo Plinio Seniore di Roma
Laurea in Medicina e Chirurgia (110/110 e lode) – Facolta' di Medicina
e Chirurgia dell'Universita' degli Studi di Roma "La Sapienza" (1982)
Specializzazione in Medicina Interna (70/70 e lode) presso la Facolta' di
Medicina e Chirurgia dell'Universita' degli Studi di Roma "La Sapienza"
(1987).
Lingue parlate e scritte: italiano ed inglese.
Conoscenza scolastica del francese e dello spagnolo
4
Attivita' assistenziale:
1978-1982: Allievo interno presso il reparto di I Clinica Medica
dell'Istituto di I Clinica Medica Generale e Terapia Medica
dell'Universita' degli Studi di Roma "La Sapienza".
1982-1990: Specializzando e successivamente medico volontario presso
il reparto di cui sopra.
1991: Successivamente alla presa di servizio – avvenuta con decorrenza
giuridica 10.7.1990 ed economica 15.9.1990 come Collaboratore
Tecnico VII livello – dall’1.11.1993 Funzionario Tecnico VIII livello –
conferimento della qualifica assistenziale (decorrenza: 1.1.1991) presso
la Divisione di I Clinica Medica Generale e Terapia Medica dell'Istituto
di I Clinica Medica – Università degli Studi di Roma “La Sapienza”.
1991: Inizio attivita' ambulatoriale specialistica presso il Servizio
Divisionale di Fisiopatologia dell'Ipertensione Arteriosa della stessa
struttura.
1991-1999: Continuazione attività assistenziale in corsia ed in
ambulatorio, nelle istituzioni sopra citate. Tali attività hanno termine
con la presa di servizio - in qualità di Professore Associato in Medicina
Interna – presso l’Università di L’Aquila – Facoltà di Medicina e
Chirurgia – avvenuta l’1.11.1999.
1999: Come vincitore di concorso per Professore Associato in Medicina
Interna – chiamato dalla Facoltà di Medicina e Chirurgia
dell’Università di L’Aquila (presa di servizio: 1.11.1999) – nelle more
del perfezionamento convenzionale con la ASL allora AQ4 inizia a
svolgere (dall’1.11.1999) attività assistenziale nel reparto - Medicina
Interna Universitaria 1 dell’Università di L’Aquila – Facoltà di
Medicina e Chirurgia – Ospedale San Salvatore.
2000: Ratifica dell’attività assistenziale (convenzionamento avvenuto in
data 4.1.2000) che è tutt’ora svolta dal candidato. Promuove l’apertura
dell’ambulatorio di “Ipertensione Arteriosa e Prevenzione
Cardiovascolare” afferente alla struttura di cui sopra.
2003: Prosegue l’attività dirigenziale – come Professore Associato – in
qualità però di Direttore dell’Unità Operativa Complessa di Medicina
Interna Universitaria 1 – Ospedale San Salvatore. Questo in seguito al
pensionamento del Mentore, la compianta Prof.ssa Anna Santucci, cui il
Prof. Claudio Ferri deve tutto e cui è e sarà riconoscente per sempre.
2004: Prosegue la medesima attività, ma come vincitore di concorso per
Professore Ordinario in Medicina Interna. Il concorso è stato vinto nel
5
2004, con chiamata avvenuta in data 01-11-2004 e presa di servizio
presso l’Ateneo Aquilano in data 01-03-2005.
2013: La U.O.C. di Medicina Interna Universitaria 1 diviene U.O.C. di
Medicina Interna e Nefrologia, con Direzione Universitaria sempre
assegnata al Prof. Claudio Ferri per entrambe le specialità. La U.O.C.
diretta dal Prof. Claudio Ferri è in atto strutturata in: 32 letti di degenza,
di cui almeno 4 di nefrologia, 2 letti di Ospedale diurno, 5 ambulatori
dedicati, attivi a turno 6 giorni su 7 dalle ore 09.00 alle ore 13.00 e dalle
ore 14.30 alle ore 18.00 (Ipertensione Arteriosa e Prevenzione
Cardiovascolare, Endocrinologia, Reumatologia, Medicina Interna,
Nefrologia), 1 servizio per il monitoraggio ambulatorio della pressione
arteriosa nelle 24 ore, 1 servizio di ecografia internistica, 1 servizio per
la capillaroscopia, la valutazione della vasodilatazione endotelio-
dipendente e della morfologia/funzione vascolare periferica e centrale.
Oltre a quanto sopra il Prof. Claudio Ferri è stato oppure è:
Senatore Accademico (dall’1.11.2007 al 31.12.2008: dimessosi per la
sopraggiunta incompatibilità tra Direzione della Scuola di
Specializzazione in Medicina Interna, che ha sempre mantenuto, e
l’incarico di Direttore del Dipartimento di Medicina Interna e Sanità
Pubblica, cui ha invece rinunciato, come già scritto, per mantenere la
Direzione della Scuola)
Membro della Commissione regionale per il farmaco (dal Novembre
2007). Il rinnovo dell’accettazione dell’incarico è avvenuto il giorno
09.02.2016
Direttore del Dipartimento di Medicina Interna e Sanità Pubblica
(dall’1-11-2004 al 31.12.2008).
Presidente del Consiglio dei Clinici dell’Ateneo dall’1.2.2011 al 30.10
2013.
Dall’Ottobre 2013 – essendo stato abolito nel nuovo Statuto di Ateneo
il Consiglio dei Clinici e rifondata la commissione paritetica – è
membro Universitario della commissione paritetica ASLAQ01-
Università dell’Aquila
Dal 2013 è membro effettivo, quale Clinico Universitario
(precedentemente era consulente clinico) del Comitato Etico della
ASLAQ1.
6
Attivita' didattica:
1987-1999: Attivita' tutoriale presso il reparto di I Clinica Medica
dell'Istituto di I Clinica Medica Generale e Terapia Medica
dell'Universita' degli Studi di Roma "La Sapienza".
1987-1999: Seminari per studenti e specializzandi nella struttura di cui
sopra.
1987/1988: Corso annuale di Clinica delle Minorazioni nel corso
biennale di specializzazione polivalente per personale direttivo, docente
ed educativo ai fini dell'insegnamento agli handicappati, autorizzato con
D.M. 7.11.1987.
1988-1999: Preparazione delle lezioni di Clinica Medica svolte dal
Direttore della Cattedra.
1993/1994 Professore a contratto del corso integrativo di Metodologia
Clinica e Semeiotica Medica - corso ufficiale Medicina Interna - nel
corso di laurea in Odontoiatria e Protesi dentaria della Facolta' di
Medicina e Chirurgia dell'Universita' degli Studi di L'Aquila.
1994/1995 Professore a contratto del corso integrativo di Metodiche
diagnostiche nella malattia ipertensiva - corso ufficiale Nefrologia
Medica - nel corso di Laurea in Medicina e Chirurgia della suddetta
Facolta'.
1995/1996 e 1996/1997 Professore a contratto del corso integrativo di
Tecniche di studio di fisiopatologia cardiorespiratoria - corso ufficiale
Fisiopatologia Cardiorespiratoria - nella Scuola di Specializzazione in
Cardiologia della suddetta Facolta'.
1997/98 Professore a contratto del corso integrativo di Tecniche di
studio di fisiopatologia cardiorespiratoria - corso ufficiale
Fisiopatologia Cardiorespiratoria - nella Scuola di Specializzazione in
Cardiologia della suddetta Facolta'.
Dall' VIII ciclo permanentemente fino al ciclo attualmente in corso:
Esperto nel Dottorato di Ricerca in Medicina Interna con sedi
consorziate L'Aquila e Roma (dalla presa di servizio presso l’Ateneo
Aquilano è docente nello stesso Dottorato di Ricerca, con sede in
7
L’Aquila, che ha assunto la definizione di “Medicina Interna ed
Immunologia Clinica”).
Successivamente alla presa di servizio nell’Ateneo di L’Aquila come
Professore Associato in Medicina Interna (concorso vinto nel 1999,
presa di servizio avvenuta l’1.11.1999) ha iniziato ad insegnare nel
corso di Laurea specialistica in Medicina, in altri Corsi di Laurea e nelle
Scuole di Specializzazione e ha continuato tale attività come Professore
Ordinario in Medicina Interna (concorso vinto nel 2004, presa di
servizio avvenuta il 01.03.2005).
Dall’ Anno Accademico 2005-2006 è Direttore della Scuola di
Specializzazione in Medicina Interna e Coordinatore del Dottorato in
Medicina Interna ed Immunologia Clinica (incarico terminato con la
soppressione di tale Dottorato e la confluenza in quello di Medicina
Clinica e Sanità Pubblica).
Dal Dicembre 2018 è coordinatore del Dottorato di ricerca in Medicina
Clinica e Sanità Pubblica dell’Ateneo dell’Aquila – Dipartimento
MeSVA
Attualmente, è Membro del Consiglio Didattico del Corso di Laurea in
Medicina e Chirurgia. Come Professore Ordinario in Medicina Interna
(chiamata avvenuta in data 01-11-2004 e presa di servizio presso
l’Ateneo Aquilano avvenuta in data 01-03-2005), insegna:
Corso di Laurea Specialistica in Medicina e Chirurgia
Corso Integrato (CI) di Malattie del rene e delle vie urinarie:
Nefrologia
Corso Integrato di Semeiotica e Metodologia clinica: Semeiotica
generale e metodologia clinica
Corso Integrato (CI) di Medicina Interna II e Geriatria: Medicina
Interna
Corso Integrato (CI) di Medicina Interna III e Geriatria: Medicina
Interna
8
Corso Integrato (CI) di Medicina Interna, endocrinologia,
immunologia clinica e malattie infettive: Malattie del rene e
dell’apparato cardiovascolare
Scuole di Specializzazione
• Medicina Interna (di cui è Direttore)
Medicina Interna
• Urologia
Patologia integrata e semeiotica funzionale e strumentale:
Nefrologia
• Chirurgia maxillo-facciale
Patologia medica e chirurgia testa collo: Patologia medica
testa-collo
• Geriatria
Malattie metaboliche e del ricambio
• Oncologia Medica
Nefrologia
• Otorinolaringoiatria
Patologia medica testa-collo
9
• Radiodiagnostica e Radioterapia
Clinica e Chirurgia in Diagnostica per immagini e
Radioterapia: il trattamento medico delle patologie dei vari
organi ed apparati
10
Attivita' Societaria:
Socio ordinario della Societa' Italiana di Medicina Interna, della
Societa' Italiana dell'Ipertensione Arteriosa e della Società Italiana di
Prevenzione Cardiovascolare.
Consigliere nazionale e già tesoriere della Società Italiana
dell’Ipertensione Arteriosa.
Attualmente è Presidente della medesima Società.
Consigliere nazionale della Società Italiana di Prevenzione
Cardiovascolare
Membro del Council for High Blood Pressure Research della American
Heart Association.
Membro della European Society of Hypertension.
Clinic Hypertension Specialist della European Society of Hypertension
(qualifica conferita su invito della Società Europea, dietro indicazione
della Società Italiana dell’Ipertensione Arteriosa).
11
Riviste e attività di reviewer
Reviewer per il Congresso annuale della Società Italiana
dell'Ipertensione Arteriosa.
Reviewer per il Congresso della Società Europea dell’Ipertensione
Arteriosa.
Reviewer per Circulation, Journal of Hypertension, Diabetes, Diabetes
Care, Diabetologia etc.
Membro del board di ”Ipertensione Arteriosa e Prevenzione
Cardiovascolare”.
Membro del board di Nutrition, Metabolism and cardiovascular disease
Membro del board di Journal of Hypertension
Membro del board di International Journal of Cardiology -
Hypertension
Revisore dei progetti di finanziamento del Ministero dell’Università e
della Ricerca Scientifica.
12
Attività scientifica
L’attività scientifica del Prof. Ferri è provata, oltre che dai numerosi
progetti nazionali ed internazionali cui prende parte oppure coordina e
dall’intensa attività congressuale nazionale ed internazionale come
relatore invitato, da 255 pubblicazioni a stampa su riviste peer
reviewed. Il Prof. Ferri è anche autore di circa 300 pubblicazioni in
lingua italiana, che non vengono qui elencate per brevità espositiva e
perché la loro lista cartacea e su file è andata smarrita per il crollo dello
studio personale nel sisma aquilano del 2009.
Oltre a quanto sopra, il Prof. Ferri ha curato la traduzione di numerosi
libri di uso comune per studenti in Medicina e specializzandi in
Medicina Interna ed in Cardiologia ed è co-autore di diversi libri per
studenti, ultimo uscito nel 2013 il libro “La nutraceutica” edito
dall’Ateneo di Bologna.
Il Prof. Ferri fruisce oppure ha fruito di molteplici finanziamenti
nazionali ed internazionali, finalizzati alla conduzione di studi clinici
e/o sperimentali. Ultimi finanziamenti dalla Azienda Unilever per uno
studio sugli effetti cardiovascolari del tè e dalla Fondazione Carispaq
per uno studio da condursi nel territorio aquilano.
I filoni di ricerca dell’attività scientifica svolta dal prof. Ferri hanno
riguardato principalmente il metabolismo del sodio nel contesto della
etiopatogenesi e terapia dell’ipertensione arteriosa, la funzione
endoteliale e – da circa 10 anni – il ruolo dell’alimentazione e di alcuni
micro- e macronutrienti nell’influenzare la regolazione pressoria e la
sensibilità insulinica. Molti tra gli studi svolti dal Prof. Ferri sono
condotti insieme a prestigiosi gruppi di ricerca nazionali ed
internazionali.
Pubblicazioni peer reviewed (H index SCOPUS = 51, citazioni SCOPUS = 10955)
1) Relationship between vasopressin and the renin angiotensin aldosterone system in
essential hypertension: effect of converting enzyme inhibition on plasma vasopressin.
A.Santucci, R.Leonetti Luparini, Claudio Ferri, C.Ficara, C.Giarrizzo. J Hypertens
1985, 3(suppl 2):S133-S134.
13
2) Comparative study of the antihypertensive efficacy of fixed combinations of
hydrochlorothiazide either with captopril or amiloride. C.Giarrizzo, C.Ficara, Claudio
Ferri, R.Leonetti Luparini, G.Botta, A.Santucci. Curr Ther Res 1988, 44,5:731-736.
3) Effects of angiotensin converting enzyme inhibition on platelet angiotensin II
content. A.Santucci, Claudio Ferri, R.Leonetti Luparini, MA Del Porto, C.De
Angelis, C.Ficara, F.Balsano. Am J Med 1988, 84(suppl 3A):119- 121.
4) Effect of nicardipine on angiotensin II platelet content. Claudio Ferri, A. Santucci,
R. Leonetti Luparini, MA Del Porto, C. De Angelis, C. Giarrizzo, C. Ficara e F.
Balsano. JHypertens 6 (suppl 1):S117-S119, 1988.
5) Blood platelets and angiotensin II: angiotensin II release after platelet aggregation.
Claudio Ferri, C. De Angelis, MA Del Porto, R. Leonetti Luparini, C. Giarrizzo, A.
Santucci, F. Balsano. J Hypertens 1988, 6(suppl 1):S69-s71.
6) Captopril does not alter metabolic control in elderly hypertensive diabetics during
secondary failure. G. De Mattia, O. Laurenti, G. Tullo, R. Ziantoni, Claudio Ferri, C.
Ventura, J Hypertens 1988, 6(suppl 1):S113-S115.
7) Hypertensive emergencies in old age: effects of angiotensin converting enzyme
inhibition. V. Marigliano, D. Santilli, M. Fiorani, M. Cacciafesta, Claudio Ferri, G.
Piccirillo. J Hypertens 1988, 6(suppl 1):S91-S93.
8) Evidence for sidedness of the baroceptor regulation of atrial natriuretic peptide in
normal human subjects. A.Santucci, V.Marigliano, I.Cammarella, Claudio Ferri,
R.Leonetti Luparini, C.De Angelis. In: "Progress in atrial peptide research" Eds.
Brenner BM, Laragh JH, Raven Press, New York 1989, 476- 480 (NB: trattasi di
articolo edito in un libro, e non pubblicato su rivista).
9) Angiotensin converting enzyme and quality of life: a randomized controlled trial.
A. Santucci, F. Puccetti, C. Ficara, M. Franchi, C. Giarrizzo, F. Landini, Claudio
Ferri, G. Botta, T. Di Perri. Curr Ther Res 1989, 46,5:849-857.
10) A comparison of the metabolic effects of short-term treatment with captopril,
hydrochlorothiazide, and captopril plus hydrochlorothiazide in patients with essential
hypertension. Claudio Ferri, C.Giarrizzo, R. Leonetti Luparini, G. Germano', A.
Buonanno, A. Santucci, F. Balsano. Advances in Therapy 1989, 6,5: 237-241.
11) Modulatory role of the peripheral dopaminergic system on factors regulating renal
sodium handling in elderly hypertensive patients. C. Giarrizzo, C. Ficara, C. De
Angelis, Claudio Ferri, R. Leonetti Luparini, R. Onofri, V. Marigliano, A. Santucci.
Curr Ther Res 1989, 46,5:903-907.
12) Influence of angiotensin converting enzyme inhibition on psychometric tests in
elderly hypertensives. D. Santilli, E. Bagaglini M. Cacciafesta, Claudio Ferri, D.
Brioli, V. Marigliano. Curr Ther Res 1989, 45,1:128-132.
13) Antihypertensive efficacy of low-dosage angiotensin converting enzyme
inhibition in elderly patients with mild or moderate hypertension. V. Marigliano, M.
Cacciafesta, Claudio Ferri, G. Piccirillo, D. Santilli, E. Bagaglini. Curr Ther Res
1989, 46,1:180-186.
14) Long-term captopril treatment in elderly hypertension. V. Marigliano, D. Santilli,
L. Meliffi, M. Cacciafesta, Claudio Ferri, G. Piccirillo, F. Robinson, A. Tagliaccica,
G. Tagliaccica. Curr Ther Res 1989, 46,5:858-865.
14
15) Plasma atrial natriuretic peptide in young hypertensives and in young
normotensives subjects with a family history of hypertension and in young
hypertensive patients. A. Santucci, Claudio Ferri, I. Cammarella, S. Tani, A. Musca,
F. Balsano. Am J Hypert 1990 3:10-15.
16) Atrial natriuretic factor behaviour in hypertensive diabetic patients. G. De Mattia,
Claudio Ferri, M Tullo, O. Laurenti, C. Giarrizzo, C. Ventura, A. Santucci. In:
Diabetes, obesity and hyperlipidemias - IV. Crepaldi G, Tiengo A, Enzi G (Eds.).
Elsevier Science Publishers B.V. (Biomedical Division) 1990, 451-453. (NB: trattasi
di articolo edito in un libro, e non pubblicato su rivista).
17) Efficacy and safety evaluation of a fixed combination of captopril 50
mg/hydrochlorothiazide 15 mg in hypertensive diabetic patients. A.Santucci, G. De
Mattia, C. Giarrizzo, O. Laurenti, Claudio Ferri, A.Piccoli, G.Botta, F.Balsano.
Advances in Therapy 1990, 7,1:28-32.
18) Efficacy and safety of nitrendipine therapy in moderate essential hypertension.
C.Giarrizzo, Claudio Ferri, G.Germano', R.Leonetti Luparini, MA Del Porto,
C.Bellini, A.Santucci, F.Balsano. Advances in Therapy 1990,7,1:38:42.
19) Once-daily administration of captopril plus hydrochlorothiazide in patients with
essential hypertension. A biometrical approach for investigating its effects on blood-
pressure circadian rhytm. G. Germano', S.Damiani, V. Pecchioli, U. Germano', C.
Giarrizzo, Claudio Ferri, R. Leonetti Luparini, A. Santucci, F. Balsano. Curr TherRes
1990, 47, 6:940- 951.
20) Circadian Blood pressure, heart rate, and endocrine variations in young healthy
and mesor- hypertensive men. G. Germano', Claudio Ferri, I. Cammarella, C. Bellini,
A. Santucci, A. Germani, A. Musca, F. Balsano, Y Li, G. Cornelissen, F. Halberg. In:
New Trends in Autonomic nervous system research. Yoshikawa M et al EDS, Elsevier
1991 576-580. (NB: trattasi di articolo edito in un libro, e non pubblicato su rivista).
21) Effects of dopamine infusion on plasma atrial natriuretic peptide in normal
subjects. A. Piccoli, A. Carlomagno, Claudio Ferri,C. Bellini, R. Leonetti Luparini, C.
Giarrizzo, L. Di Francesco, A. Santucci, F. Balsano. Curr Ther Res 1991, 50, 6:780-
785.
22) Sodium metabolism during altitude acclimatization. C. De Angelis, S. Farrace, L.
Urbani, S. Porcu', Claudio Ferri, R. D'Amelio. Med Aer Spatial 1991, 30,119:309-
314.
23) Does mild autonomic neuropathy affect atrial natriuretic factor regulation in
diabetic hypertensive patients ? G. De Mattia, O. Laurenti, C. Bravi, Claudio Ferri, C.
Bellini, C. De Angelis, C. Giarrizzo, A. Santucci, F. Balsano. Am J Hypertens 1991,
4:832-835.
24) Plasma insulin levels do not change during atrial natriuretic factor infusion in
human essential hypertensives. Claudio Ferri, G. De Mattia, A. Piccoli, A.
Carlomagno, R. Leonetti Luparini, G. Germano', C. Giarrizzo, G. Torregrossa, A.
Santucci, F. Balsano. Am J Hypertens 1991, 4:880-884.
25) 23Na-NMR study of cation cotransport in human red blood cells. M. Cacciafesta,
V. Marigliano, Claudio Ferri, G. Piccirillo, L. Guidoni, AM. Luciani, A. Rosi, V.
Viti. Am J Physiol 1992, 262 (Cell Physiol): 1292-1296
26) Natriuretic hormones in young hypertensives and in young normotensives with or
without a family history of hypertension. A. Musca, I. Cammarella, Claudio Ferri, C.
15
Bellini, R. Ruggeri, A. Santucci, F. Balsano. Am J Hypertens 1992, 5:592-599.
27) Blood pressure nychtohemeral rhythm changes in early and intermediate stages of
renal failure. G. Germano', S. Damiani, U. Germano', C. Giarrizzo, Claudio Ferri, R.
Leonetti Luparini, A. Santucci, F. Balsano. J Ambulat Monit 1992, 5,1:41-50.
28) 23Na NMR evaluation of human erythrocytes Na+/K+/Cl- cotransport. A study in
elderly hypertensives. M. Cacciafesta, Claudio Ferri, G. Piccirillo, C. Bellucci, L.
Persichino, V. Marigliano, M. Delfini, A. Miccheli. Cell Mol Biol 1992, 32(8):877-
884.
29) Effects of high altitude exposure on plasma and urinary digoxin-like substance. C.
De Angelis, S. Farrace, L. Urbani, S. Porcu', Claudio Ferri, R. D'Amelio, A. Santucci,
F. Balsano. Am J Hypertens 1992, 5:600-607.
30) Enhanced blood pressure response to ciclooxygenase inhibition in salt-sensitive
human essential hypertension. Claudio Ferri, C. Bellini, A. Piccoli, A. Carlomagno,
MS Bonavita, A. Santucci, F. Balsano. Hypertension 1993, 21:875-881
31) Octreotide, a somatostatin analog, reduces insulin secretion and increases renal
Na+ excretion in lean essential hypertensive patient. Claudio Ferri, G. De Mattia, C.
Bellini, O. Laurenti, C. Bravi, R. Baldoncini, M.S. Bonavita, A. Santucci. Am J
Hypertens 1993, 6:276-281.
32) The influence of salt sensitivity on the blood pressure response to exogenous
kallikrein in essential hypertensive patients. C. Bellini, Claudio Ferri, A. Piccoli, A.
Carlomagno, L. Di Francesco, MS Bonavita, A. Santucci, F. Balsano. Nephron 1993,
65:28-35.
33) Oxygen administration increases plasma digoxin-like substance and renal sodium
excretion in chronic hypoxic patients. C. De Angelis, A. Perrone, Claudio Ferri, A.
Piccoli, C. Bellini, R. D'Amelio, A. Santucci, F. Balsano. Am J Nephrol 1993, 13:173-
177.
34) Renal sodium excretory function during acute oxygen administration. L. De Siati,
R. Baldoncini, C. De Angelis, Claudio Ferri, A. Santucci, A. Perrone, F. Balsano.
Respiration 1993, 60:338-342.
35) Increased sodium,potassium cotransport activity in salt-sensitive essential
hypertensive patients. M. Cacciafesta, Claudio Ferri, A. Carlomagno, G. Piccirillo, C.
De Angelis, A. Santucci, L. Guidoni, AM Luciani, A. Rosi, V. Viti, F. Balsano. J
Hypertens 1993, 11(Suppl 5):S254-S255.
36) Urinary kallikrein excretion and plasma atrial natriuretic peptide in human salt-
sensitive hypertension. Claudio Ferri, C.Bellini, A.Carlomagno, L.De Siati,
A.Perrone, A.Santucci, F.Balsano. J Hypertens 1993,11(Suppl 5):212-3.
37) Effects of short-time insulin suppression on renal sodium excretion in type II
diabetic hypertensives. A. Porzano, C. Bellini, Claudio Ferri, O. Laurenti, G. De
Mattia, A. Santucci, F. Balsano. Diab Res 1993, 22:3-10.
38) Atrial natriuretic peptide in non-modulating essential hypertension. R. Leonetti
Luparini, Claudio Ferri, A. Santucci, F. Balsano. Hypertension 1993, 21:803-809.
39) Salt-sensitivity is associated with a hyperinsulinaemic and hyperglycaemic
response to atrial natriuretic peptide infusion in human essential hypertension.
Claudio Ferri, C. Bellini, G. Desideri, L. Di Francesco, G. de Mattia, A. Santucci, F.
16
Balsano. Diabetologia 1994, 37:308-312.
40) Abnormal atrial natriuretic peptide and renal responses to saline infusion in
nonmodulating essential hypertensive patients. Claudio Ferri,C. Bellini, R.
Baldoncini, R. Leonetti Luparini, A. Perrone, A. Santucci. Circulation 1994, 90:2859-
2869.
41) Erythrocyte Na-K-Cl cotransport activity in low renin essential hypertensive
patients. A 23Na Nuclear Magnetic Resonance study. M. Cacciafesta, Claudio Ferri,
A. Carlomagno, C. De Angelis, L. Guidoni, AM Luciani, A. Rosi, V. Viti, A.
Santucci, F. Balsano. Am J Hypertens 1994, 7:151-158.
42) Atrial natriuretic factor in hypertensive and normotensive diabetic patients.
Claudio Ferri, A. Piccoli, C. Bellini, O. Laurenti, G. De Mattia, A. Santucci, F.
Balsano. Diabetes Care 1994, 3: 195-200.
43) Influence of the renin profile on the blood pressure response to different doses of
hydrochlorothiazyde plus either quinapril or captopril. Claudio Ferri, L. Di Francesco,
A. Perrone, R. Baldoncini, G. Veneto, G. Raule, C. Bellini. Drug Invest 1994,
7(6):340-345.
44) Urinary kallikrein and salt sensitivity in essential hypertensive males. Claudio
Ferri, C. Bellini, A. Carlomagno, A. Perrone, A. Santucci. Kidney Int 1994, 46:780-
788.
45) Plasma endogenous digoxin-like substance levels are dependent on blood O2 in
man. Claudio Ferri, C. Bellini, C. De Angelis, A. Perrone, A. Santucci. Clin Sci 1994,
87:447-451.
46) Effects of atrial natriuretic factor infusion on plasma prorenin levels in
hypertensive males. R. Baldoncini, Claudio Ferri, L. De Siati, C. Bellini, A. Santucci.
Clin Exp Hypertens 1994, 16(3):283-302.
47) Abnormal atrial natriuretic peptide and renal responses to saline infusion in
nonmodulating essential hypertensive patients. Claudio Ferri,C. Bellini, R.
Baldoncini, R. Leonetti Luparini, A. Perrone, A. Santucci. Circulation 1994, 90:2859-
2869.
48) Plasma endothelin-1 levels in obese hypertensive and normotensive men.Claudio
Ferri, C Bellini, G. Desideri, L. Di Francesco, R. Baldoncini, A. Santucci, G. de
Mattia. Diabetes 1995, 44:431-436.
49) Circulating endothelin-1 levels in lean non- insulin-dependent diabetic patients.
Influence of ACE- inhibition. Claudio Ferri, O. Laurenti, C. Bellini, MR Cassone
Faldetta, G. Properzi, A. Santucci, G. De Mattia. Am J Hypertens 1995, 8:40-46.
50) Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic
clamp in NIDDM men.Claudio Ferri, A. Carlomagno, R. Baldoncini, MR Cassone
Faldetta, O. Laurenti, G. Properzi, A. Santucci, G. De Mattia. Diabetes Care 1995,
18:226-233.
51) The effect of insulin on endothelin-1 (ET-1) secretion in human cultured
endothelial cell (letter). Claudio Ferri, G. De Mattia. Metabolism 5, 1995:689-690.
52) Hormonal and renal responses to atrial natriuretic peptide infusion in low renin
hypertension. Claudio Ferri, R. Baldoncini, C. Bellini, L. Di Francesco, R. Leonetti
Luparini, A. Santucci. Am J Nephrol 1995, 15:222-229.
17
53) Circulating endothelin-1 concentrations in patients with chronic hypoxia. Claudio
Ferri,C. Bellini, C. De Angelis, L. De Siati, A. Perrone, G. Properzi, A. Santucci. J
Clin Pathol 1995, 48:519-524.
54) Demonstration of Rickettsia Conorii-induced coagulative and platelet activation in
vivo in patients with mediterranean spotted fever. G. Davi', Vigneri S, Ganci A,
Claudio Ferri, Di Francesco L, Vitale G, Mansueto S. Thromb Haemostas 1995,
74(2):631-634.
55) Active kallikrein response to changes in sodium chloride intake in essential
hypertensive patients. Claudio Ferri, C. Bellini, A. Carlomagno, G. Desideri, A.
Santucci. J Am Soc Nephrol 1996, 7:443-453.
56) Impaired inactive to active kallikrein conversion in human salt sensitive
hypertension. C. Bellini, Claudio Ferri, A.Carlomagno, S. Necozione, A. Lepore, G.
Desideri, A. Santucci. J Am Soc Nephrol 1996, 7:2565-2577.
57) Effect of aprotinin on insulin sensitivity in non- insulin-dependent diabetes
mellitus. O. Laurenti, A. Piccoli, C. Bravi, M. Cassone Faldetta, C. Bellini, Claudio
Ferri, G. De Mattia. Diabetic Medicine 1996.
58) Plasma and urinary digitalis-like substance levels during atrial natriuretic peptide
infusion in essential hypertensive patients. R. Baldoncini, Claudio Ferri, C. Bellini, G.
Desideri, C. De Angelis, A. Santucci. Clin Invest Med 1996, 19,1:1-16
59) Circulating catecholamines and metabolic effects of captopril effects of captopril
in NIDDM patients. G. De Mattia, Claudio Ferri, O. Laurenti, M Cassone Faldetta, A.
Piccoli, A. Santucci. Diabetes Care 1996, 19,3:226-230
60) Endogenous insulin modulates circulating endothelin-1 concentrations in humans.
Claudio Ferri, C. Bellini, G Desideri, G De Mattia, A. Santucci. Diabetes Care 1996,
19:504-506
61) Elevated levels of plasma endothelin-1, von Willebrand Factor, and urinary
albumin excretion in three relatives with pseudoxanthoma elasticum. A. Piccoli, D
Ricciardi, A. Santucci, V. Barnaba, Claudio Ferri. Thromb Haemostas 1996,
76(2)275-277
62) Dysfonction endothéliale dans l'hipertension artérielle sensible au sel.. C.Ferri,
C.Bellini, G. Desiseri, L.Di Francesco, G.De Mattia, A.Santucci. Arch. Mal Coeur
Vaiss. 1996, 89:971-974.
63)Effect of acute exposure to hypoxia on electrolytes and water metabolism
regulatory hormones. C. De Angelis, Claudio Ferri, L. Urbani, S. Farrace. Aviat
Space Environ Med 1996, 67:746-750
64) Elevated albumin excretion in nonmodulating essential hypertensive patients. R.
Baldoncini, C. Bellini, G. Desideri, C. De Angelis, Claudio Ferri, A. Santucci.
Nephron 1997, 76:264-269
65) Elevated plasma and urinary endothelin-1 levels in human salt-sensitive
hypertension. Claudio Ferri, C. Bellini, G. Desideri, C. Mazzocchi, L. De Siati, A.
Santucci. Clin Sci 1997, 93:35-41
66) Circulating endothelin-1 levels in obese patients with the metabolic syndrome.
Claudio Ferri, C. Bellini, G. Desideri, R. Baldoncini, G. Properzi, A. Santucci, G. De
18
Mattia. Exp Clin Endocrinol Diabetes 1997, 105(Suppl 2):38-40
67) Increased levels of plasma endothelin-1 in non-insulin-dependent diabetic patients
with retinopathy but without other diabetes-related organ damage. O. Laurenti, EM
Vingolo, G Desideri, Claudio Ferri, C. Bellini, M. Cassone, A. Santucci, G. De
Mattia. Exp Clin Endocrinol Diabetes 1997 105(Suppl 2):41-42
68) Poliol pathway activation and glutathione redox status in non-insulin-dependent
diabetic patients. MC Bravi, P.Pietrangeli, O. Laurenti, MC Cassone-Faldetta, Claudio
Ferri, Giancarlo De Mattia. Metabolism 1997, 46:1194-1198
69) Isolation and characterization of a digoxin-like immunoreactive substance from
human urine by affinity chromatography. C. De Angelis, M. Riscazzi, R. Salvini, A.
Piccoli, Claudio Ferri, A. Santucci. Clin Chem 1997, 43:1416-1420
70) Endothelin-1 in diabetic and nondiabetic men with erectile dysfunction. S.
Francavilla, G. Properzi, C. Bellini, Claudio Ferri, A. Santucci. J Urol 1997,
158:1770-1774
71) Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1
secretion. In vitro and in vivo studies. G. Desideri, Claudio Ferri, C. Bellini, G. de
Mattia, A. Santucci. Diabetes 1997, 46:81-86.
72)Elevated plasma endothelin-1 levels as an additional risk factor in non-obese
essential hypertensive patients with metabolic abnormalities. Claudio Ferri, C.
Bellini, G. Desideri, R. Baldoncini, L. de Siati, A. Santucci. Diabetologia 1997
40:100-102.
73) Age, gender, and non-modulation. A sexual dimorphism in essential hypertension.
N.D.L. Fisher, Claudio Ferri, C. Bellini, A. Santucci, R. Gleason, G.H. Williams,
N.K. Hollenberg, E.W. Seely. Hypertension 1997, 29:980-985.
74) Role of plasmaand urinary endothelin-1 in early diabetic and hypertensive
nephropathy. G. De Mattia, M. Cassone Faldetta, C. Bellini, O. Laurenti, R.
Baldoncini, A. Santucci, Claudio Ferri. Am J Hypertens 1998, 11:983-988.
75) Influence of reduced glutathione infusion on glucose metabolism in patients with
non-insulin-dependent diabetes mellitus. G. De Mattia, MC Bravi, O. Laurenti, M.
Cassone-Faldetta, A.Armiento, Claudio Ferri, F. Balsano. Metabolism 1998, 8:993-
997.
76) Age, gender, and non-modulation. A sexual dimorphism in essential hypertension.
N.D.L. Fisher, Claudio Ferri, C. Bellini, A. Santucci, R. Gleason, G.H. Williams,
N.K. Hollenberg, E.W. Seely. Hypertension 1997, 29:980-985.
77) Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases
plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-
dyslipidemic, normotensive patients with non-insulin.dependent diabetes. G. De
Mattia, M.C. Bravi, O. Laurenti, M Cassone-Faldetta, A. Proietti, O. De Luca, A.
Armiento, Claudio Ferri. Diabetologia 1998, 41:1392-1396.
78) Clustering of endothelial markers of vascular damage in human salt-sensitive
hypertension. Influence of dietary sodium load and depletion. Claudio Ferri, C.
Bellini, G. Desideri, E. Giuliani, L. De Siati, S. Cicogna, A. Santucci. Hypertension
1998, 32:862-868.
79) Enhanced activity of sodium-lithium countertransport in patients with cardiac
19
sydrome X: a potential link between cardiac and metabolic syndrome X. A.
Gaspardone, Claudio Ferri, F. Crea, F. Versaci, F. Tomai, A. Santucci, L. Chiarello,
P.A. Gioffrè. J Am Coll Cardiol 1998, 32:2031-2034.
80) Angiotensin II increases the release of endothelin-1 from cultured endothelial cells
but does not regulate its circulating levels. Claudio Ferri, G. Desideri, R. Baldoncini,
M. Valenti, A. Santucci, G. De Mattia. Clin Sci 1999, 95:261-270.
81) Effects of naloxone on myocardial ischemic preconditioning in man. F. Tomai, F.
Crea, A. Gaspardone, F. Versaci, AS Ghini, Claudio Ferri, G. Desideri, L. Chiariello,
PA Gioffrè. J Am Coll Cardiol 1999, 33:1863-1869.
82) Decreased activity of the red blood cell ATPase-dependent Na+ pump in patients
with cardiac syndrome X. Claudio Ferri, G Desideri, G. de Mattia, C. Bellini, M.
Gentile, P Gioffrè, A. Santucci, A. Gaspardone. Clin Sci 1999, 97:369-375.
83) High plasma renin activity is combined with elevated urinary albumin excretion in
essential hypertensive patients. R. Baldoncini, G Desideri, C. Bellini, M. Valenti, G de
Mattia, A. Santucci, Claudio Ferri. Kidney Int 1999, 56:1499-1504.
84) Relationship between insulin resistance and nonmodulating hypertension. Linkage
of metabolic abnormalities and cardiovascular risk. Claudio Ferri, C. Bellini, G.
Desideri, M. Valenti, G. de Mattia, A. Santucci, N.K. Hollenberg, G.H. Williams.
Diabetes 1999: 48:1623-1630.
85) Altered adrenal sensitivity to angiotensin II in low renin essential hypertension.
N.D.L. Fisher, S. Hurwitz, Claudio Ferri, X. Jeunemaitre, N.K. Hollenberg, G.H.
Williams. Hypertension 1999, 34:388-394 (Articolo con commento editoriale di DG
Warnock).
86) Effects of insulin on in vitro vascular cell adhesion molecule-1 expression and in
vivo soluble VCAM-1 release. G. de Mattia, M.C. Bravi, A. Costanzo,O. Laurenti, M.
Cassone Faldetta, A. Armiento, O. De Luca MD,Claudio Ferri. Diabetologia 1999,
42:1235-1239.
87) Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-expression by
human vascular endothelial cells and increases soluble ICAM-1 release in vivo. L.
Pastore, A. Tessitore, S. Martinotti, E. Toniato, E. Alesse, M.C. Bravi, Claudio Ferri,
G. Desideri, A. Gulino, A. Santucci. Circulation 1999, 100:1646-1652.
88) Early up-regulation of endothelial adhesion molecules in obesehypertensive men.
Claudio Ferri, G. Desideri, M. Valenti, C. Bellini, A. Santucci, G. de Mattia.
Hypertension 1999, 34:568-573.
89) Prediction and consistency of blood pressure salt-sensitivity as assessed by a rapid
volume expansion and contraction protocol. Salt-Sensitivity Study Group of the
Italian Society of Hypertension.Strazzullo P, Galletti F, Dessi-Fulgheri P, Claudio
Ferri, Glorioso N, Malatino L, Mantero F, Manunta P, Semplicini A, Ghiadoni L,
Zoccali C. J Nephrol 2000, 13(1):46-53
90) Renal endothelin-1 is linked to changes in urinary salt and volume in essential
hypertension. L. Malatino, I. Bellanuova, A. Cataliotti, F. Cuzzola, F. Mallamaci, G
Tripepi, S. Parlongo, S. Cutrupi, R Mangiafico, Claudio Ferri, F. Galletti, N.
Glorioso, P. Strazzullo, C. Zoccali on behalf of the SISS Group of the Italian Society
of Hypertension. J Nephrol 2000, 13:178-184.
91) Circulating vascular endothelial growth factor levels are decreased in patients with
chronic and liver cirrhosis depending on the degree of hepatic damage. G.
20
Desideri,Claudio Ferri. Clin Sci 2000, 99:159-160.
92) Endothelial activation in patients with cardiac syndrome X. G. Desideri, A.
Gaspardone, M. Gentile, A. Santucci, P.A. Gioffrè, Claudio Ferri. Circulation 2000,
102:2359-2364.
93) Blood endothelin-1 levels before and after carotid endoartherectomy for
atherosclerotic stenosis. G Properzi, F Francavilla, C. Bellini, P. D’Abrizio, B.
Mangiacotti, Claudio Ferri, C. Spartera, A. Santucci, S. Francavilla. Atherosclerosis
2001, 154:137-140
94) Urinary adrenomedullin is related to ET-1 and salt intake in patients with mild
essential hypertension. Salt Sensitivity Group of Italian Society of Hypertension.
Cuzzola F, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Cataliotti A, Stancanelli B,
Malatino L, Bellanuova I, Claudio Ferri, Galletti F, Filigheddu F, Glorioso N,
Strazzullo P, Zoccali C. Am J Hypertens 2001, 3:224-230
95) The influences of obesity and glycemic control on endothelial activation in
patients with type 2 diabetes. W. Bagg, Claudio Ferri, G Desideri, G. Gamble, P.
Ockleford, G. D. Braadtvedt. J Clin Endocrinol Metab 2001, 86(11)5491-5497.
96) Prolonged, low dose -tocopherol therapy counteracts intercellular cell adhesion
molecule-1 activation. G Desideri, G Croce, MC Marinucci, P Masci, M Stati, L
Valeri, A. Santucci, Claudio Ferri. Clin Chim Acta 2002, 320:5-9
97) Patterns of myocardial endothelin-1 expression and outcome after cardiac
transplantation. Claudio Ferri, G. Properzi, G. Tomassoni, A. Santucci, G. Desideri,
A.E. Giuliani, R. Starling, N.B. Ratliff, D.J. Cook, P. McCarthy, Y.B.Young, M.H.
Yamani. Circulation 2002, 105:1768-1771.
98) Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and
von Willebrand factor levels and increase nitric oxide concentrations in
hypercholesterolemic patients. G. Desideri, M.C.Marinucci, G. Tomassoni, P. Masci,
A. Santucci, Claudio Ferri. J Clin Endocrinol Metab 2002, 87:2940-2945.
99) Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and
von Willebrand factor levels and increase nitric oxide concentrations in
hypercholesterolemic patients. G. Desideri, M.C.Marinucci, G. Tomassoni, P. Masci,
A. Santucci, Claudio Ferri. J Clin Endocrinol Metab 2002, 87:2940-2945.
100) Effects of carbon-coated coronary stents on the markers of inflammation,
thrombin generation and platelet and endothelial activation. F. Tomai, A. Ghini,
Claudio Ferri, G. Desideri, F. Versaci, A. Gaspardone, L. Altamura, G. Magliano, F.
Crea, L. Chiariello. Ital Heart J 2003, 4(1):23-28
101) Controlled analysis of blood pressure sensitivity to sodium intake: interactions
with hypertension type. S. Hurwitz, N.D.L. Fisher, Claudio Ferri, PN. Hopkins, G.H.
Williams, N.K. Hollenberg. J Hypertens (previsto per vol 21:943-950 del 2003, con
commento editoriale di C. Zoccali)
102) Angiotensin II inhibits endothelial cell motility through an AT1-dependent
oxidant-sensitive decrement of nitric oxide availability. G. Desideri, MC Bravi, M.
Tucci, G. Croce, MC Marinucci, E. Alesse, Claudio Ferri. Arterioscl Thromb Vasc
Biol (previsto per il numero di giugno 2003)
103) Effects of obesity and weight loss on soluble CD40L levels. G. Desideri, Claudio
Ferri. JAMA 2003, 289:1781-1782.
104) Endothelial cell activation in men with erectile dysfunction without
21
cardiovascular risk factors and overt vascular damage. Bocchio M, Desideri G,
Scarpelli P, Necozione S, Properzi G, Spartera C, Francavilla F, Ferri C, Francavilla
S. J Urol. 2004 Apr;171(4):1601-4.
105) Does nondipping blood pressure profile contribute to vascular inflammation
during sleep deprivation?Desideri G, Croce G, Ferri C. J Am Coll Cardiol. 2004 Oct
6;44(7):1529-30.
106) Endothelial function and dysfunction. Part I: Methodological issues for
assessment in the different vascular beds: a statement by the Working Group on
Endothelin and Endothelial Factors of the European Society of Hypertension.
Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A,
Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL,
Taddei S, Webb DJ; Working Group on Endothelin and Endothelial Factors of the
European Society of Hypertension. J Hypertens. 2005 Jan;23(1):7-17.
107) Short-term administration of dark chocolate is followed by a significant increase
in insulin sensitivity and a decrease in blood pressure in healthy persons. Grassi D,
Lippi C, Necozione S, Desideri G, Ferri C. Am J Clin Nutr. 2005 Mar;81(3):611-4.
108) Early activation of vascular endothelial cells and platelets in obese
children.Desideri G, De Simone M, Iughetti L, Rosato T, Iezzi ML, Marinucci MC,
Cofini V, Croce G, Passacquale G, Necozione S, Ferri C. J Clin Endocrinol Metab.
2005 Jun;90(6):3145-52.
109) Treatment of hypertension and adherence to treatment guidelines in clinical
practice: an Italian study. Malacco E, Ferri C, Grandi AM, Kilama MO, Soglian AG,
Vigna L. Adv Ther. 2005 Mar-Apr;22(2):96-106. Endothelial activation. Sliding door
to atherosclerosis.Desideri G, Ferri C. Curr Pharm Des. 2005;11(17):2163-75.
110) Endothelial activation. Sliding door to atherosclerosis. Desideri G, Ferri C. Curr
Pharm Des. 2005;11(17):2163-75.
111) Cocoa reduces blood presure and insulin resistance and improves endothelium-
dependent vasodlation in hypertensives. Grassi D, Necozione S, Lippi C, Croce G,
Valeri L, Pasqualetti P, Desideri G, Blumberg JB, Ferri C. Hypertension. 2005
Aug;46(2):398-405.
112) Nonpharmacological treatment of hypercholesterolemia increases circulating
endothelial progenitor cell population in adults. Croce G, Passacquale G, Necozione
S, Ferri C, Desideri G. Arterioscler Thromb Vasc Biol. 2006 May;26(5):e38-9.
113) Renal damage in primary aldosteronism: results of the PAPY Study. Rossi GP,
Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M,
Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina
AC, Mantero F; PAPY Study Participants. Hypertension. 2006 Aug;48(2):232-8.
114) Cocoa beans, endothelial function and aging: an unexpected friendship? Ferri C,
Grassi D, Grassi G. J Hypertens. 2006 Aug;24(8):1471-4.
115) Limitations and discrepancies of transthoracic and transoesophageal
echocardiography compared with surgical findings in patients submitted to surgery for
complications of infective endocarditis. Cicioni C, Di Luzio V, Di Emidio L, De
Remigis F, Fragassi G, Gregorini R, Mazzola A, Paparoni S, Prosperi F, Ferri C. J
Cardiovasc Med (Hagerstown). 2006 Sep;7(9):660-6.
116) A prospective study of the prevalence of primary aldosteronism in 1,125
22
hypertensive patients. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C,
Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M,
Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D,
Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. J Am Coll
Cardiol. 2006 Dec 5;48(11):2293-300.
117) Enhanced plasma soluble CD40 ligand levels in essential hypertensive patients
with blunted nocturnal blood pressure decrease. Desideri G, Cipollone F, Valeri L,
Grassi D, Necozione S, Croce G, Passacquale G, Garofalo A, Lippi C, Mezzetti A,
Ferri C.Am J Hypertens. 2007 Jan;20(1):70-6.
118) Prospective evaluation of the saline infusion test for excluding primary
aldosteronism due to aldosterone-producing adenoma. Rossi GP, Belfiore A, Bernini
G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F,
Mannelli M, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-
Rosei E, Pessina AC, Mantero F; PAPY Study Investigators. J Hypertens. 2007
Jul;25(7):1433-42.
119) C-reactive protein: interaction with the vascular endothelium and possible role in
human atherosclerosis.Ferri C, Croce G, Cofini V, De Berardinis G, Grassi D, Casale
R, Properzi G, Desideri G. Curr Pharm Des. 2007;13(16):1631-45.
120) COX-2: friend or foe? Iezzi A, Ferri C, Mezzetti A, Cipollone F. Curr Pharm
Des. 2007;13(16):1715-21.
121) Comparison of the captopril and the saline infusion test for excluding
aldosterone-producing adenoma.Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris
B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo
G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F; Primary
Aldosteronism Prevalence in Italy Study Investigators. Hypertension. 2007
Aug;50(2):424-31.
122) Enhanced soluble CD40 ligand and Alzheimer's disease: evidence of a possible
pathogenetic role. Desideri G, Cipollone F, Necozione S, Marini C, Lechiara MC,
Taglieri G, Zuliani G, Fellin R, Mezzetti A, di Orio F, Ferri C. Neurobiol Aging. 2008
Mar;29(3):348-56.
123) Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved
activity of circulating angiogenic cells in men with cardiovascular risk factors and
erectile dysfunction. Bocchio M, Pelliccione F, Passaquale G, Mihalca R, Necozione
S, Desideri G, Francavilla F, Ferri C, Francavilla S. Atherosclerosis. 2008
Jan;196(1):313-9.
124) Nifedipine improves the migratory ability of circulating endothelial progenitor
cells depending on manganese superoxide dismutase upregulation.Passacquale G,
Desideri G, Croce G, Murgo S, Mancarelli MM, Zazzeroni F, Alesse E, Ferri C.J
Hypertens. 2008 Apr;26(4):737-46.
125) Body mass index predicts plasma aldosterone concentrations in overweight-
obese primary hypertensive patients.Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi
G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Palumbo G, Patalano
A, Rizzoni D, Rossi E, Pessina AC, Mantero F; Primary Aldosteronism Prevalence in
hYpertension Study Investigators.J Clin Endocrinol Metab. 2008 Jul;93(7):2566-71.
126) Role of combination therapy in the treatment of hypertension: focus on valsartan
plus amlodipine.Ferri C, Croce G, Desideri G.Adv Ther. 2008 Apr;25(4):300-20.
23
127) Tea, flavonoids, and nitric oxide-mediated vascular reactivity. Grassi D, Aggio
A, Onori L, Croce G, Tiberti S, Ferri C, Ferri L, Desideri G. J Nutr. 2008 Aug;138(8).
128) Morphology of atherosclerotic plaque: its feature by imaging study.Passacquale
G, Tiberti S, Ferri C, Desideri G. Curr Pharm Des. 2008;14(18):1753-60.
129) Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant,
hypertensive subjects after 15 days of consuming high-polyphenol dark
chocolate.Grassi D, Desideri G, Necozione S, Lippi C, Casale R, Properzi G,
Blumberg JB, Ferri C. J Nutr. 2008 Sep;138(9):1671-6.
130) Electrophysiological effects of short-term antihypertensive therapy.Ferri C,
Pasqualetti P, Tiberti S, Grassi D. Expert Rev Cardiovasc Ther. 2008 Nov;6(10).
131) Cardiovascular risk and cardiometabolic protection: role of glitazones.Petrazzi L,
Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri
C. J Nephrol. 2008 Nov-Dec;21(6):826-35.
132) Different effects of angiotensin converting enzyme inhibitors on endothelin-1
and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-
sensitive pathway.Desideri G, Grassi D, Croce G, Bocale R, Tiberti S, Evangelista S,
Necozione S, Di Orio F, Ferri C. Mediators Inflamm. 2008;2008:305087.
133) Practical solutions to the challenges of uncontrolled hypertension: a white
paper.Redon J, Brunner HR, Ferri C, Hilgers KF, Kolloch R, van Montfrans G. J
Hypertens Suppl. 2008 Dec;26(4):S1-14.
134) Chocolate, lifestyle, and health. Visioli F, Bernaert H, Corti R, Ferri C,
Heptinstall S, Molinari E, Poli A, Serafini M, Smit HJ, Vinson JA, Violi F, Paoletti R.
Crit Rev Food Sci Nutr. 2009 Apr;49(4):299-312.
135) Black tea consumption dose-dependently improves flow-mediated dilation in
healthy males.Grassi D, Mulder TP, Draijer R, Desideri G, Molhuizen HO, Ferri C. J
Hypertens. 2009 Apr;27(4):774-81.
136) Enhanced proatherogenic inflammation after recombinant human TSH
administration in patients monitored for thyroid cancer remnant.Desideri G, Bocale R,
Milardi D, Ghiadoni L, Grassi D, Necozione S, Taddei S, di Orio F, Pontecorvi A,
Ferri C.Clin Endocrinol (Oxf). 2009 Sep;71(3):429-33.
137) Flavonoids, vascular function and cardiovascular protection.Grassi D, Desideri
G, Croce G, Tiberti S, Aggio A, Ferri C. Curr Pharm Des. 2009;15(10):1072-84.
138) Within-patient reproducibility of the aldosterone: renin ratio in primary
aldosteronism.Rossi GP, Seccia TM, Palumbo G, Belfiore A, Bernini G, Caridi G,
Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F,
Mannelli M, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F; Primary
Aldosteronism in the Prevalence in hYpertension (PAPY) Study Investigators.
Hypertension. 2010 Jan;55(1):83-9.
139) Pelvic floor rehabilitation for continence recovery after radical prostatectomy:
role of a personal training re-educational program.Marchiori D, Bertaccini A,
Manferrari F, Ferri C, Martorana G.Anticancer Res. 2010 Feb;30(2):553-6.
140) In uno omnia: anti-thrombotic agents in challenging comorbidities.Pistoia F,
Ferri C, Desideri G, Rosano G, Sarà M. Brain Inj. 2010;24(5):792-6.
24
141) Antioxidants and beneficial microvascular effects: is this the remedy?Ferri C,
Grassi D.Hypertension. 2010 Jun;55(6):1310-1.
142) Ambulatory monitoring of systolic hypertension in the elderly:
Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST
trial).Ambrosioni E, Bombelli M, Cerasola G, Cipollone F, Ferri C, Grazioli I,
Leprotti C, Mancia G, Melzi G, Mugellini A, Mulè G, Palasciano G, Salvetti A,
Trimarco B.Adv Ther. 2010 Jun;27(6):365-80.
143) Flavonoids: antioxidants against atherosclerosis.Grassi D, Desideri G, Ferri C.
Nutrients. 2010 Aug;2(8):889-902.
144) The aldosterone-renin ratio based on the plasma renin activity and the direct
renin assay for diagnosing aldosterone-producing adenoma.Rossi GP, Barisa M,
Belfiore A, Desideri G, Ferri C, Letizia C, Maccario M, Morganti A, Palumbo G,
Patalano A, Roman E, Seccia TM, Pessina AC, Mantero F; PAPY study Investigators.
J Hypertens. 2010 Sep;28(9):1892-9.
145) Epidemiological and economic burden of metabolic syndrome and its
consequences in patients with hypertension in Germany, Spain and Italy; a
prevalence-based model.Scholze J, Alegria E, Ferri C, Langham S, Stevens W,
Jeffries D, Uhl-Hochgraeber K.BMC Public Health. 2010 Sep 2;10:529.
146) Blood pressure and cardiovascular risk: what about cocoa and chocolate?Grassi
D, Desideri G, Ferri C. Arch Biochem Biophys. 2010 Sep 1;501(1):112-5.
147) Changes in 24-hour ambulatory blood pressure monitoring during the 2009
earthquake at L'Aquila.Petrazzi L, Striuli R, Polidoro L, Properzi G, Casale R,
Pasqualetti P, Desideri G, Ferri C, Parati G. Am J Med. 2010 Oct;123(10):e1-3.
148) Oxidative stress and endothelial dysfunction: say NO to cigarette smoking!Grassi
D, Desideri G, Ferri L, Aggio A, Tiberti S, Ferri C.Curr Pharm Des.
2010;16(23):2539-50.
149) The role of Doppler ultrasound in the diagnosis of vasculogenic impotence.
Debora M, Daniele A, Alessandro B, Ferri C, Giuseppe M. Arch Ital Urol Androl.
2010 Dec;82(4):159-63.
150) Modelling the costs of care of hypertension in patients with metabolic syndrome
and its consequences, in Germany, Spain and Italy.Wille E, Scholze J, Alegria E,
Ferri C, Langham S, Stevens W, Jeffries D, Uhl-Hochgraeber K. Eur J Health Econ.
2011 Jun;12(3):205-18.
151) Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular
events: evidence from a large, multicenter, cross-sectional survey in Italy
(MIRACLES study).Mancia G, Rosei EA, Ambrosioni E, Avino F, Carolei A, Daccò
M, Di Giacomo G, Ferri C, Grazioli I, Melzi G, Nappi G, Pinessi L, Sandrini G,
Trimarco B, Zanchin G; MIRACLES Study Group. J Hypertens. 2011 Feb;29(2):309-
18.
152) Physician attitudes to blood pressure control: findings from the Supporting
Hypertension Awareness and Research Europe-wide survey. Redon J, Erdine S, Böhm
M, Ferri C, Kolloch R, Kreutz R, Laurent S, Persu A, Schmieder RE; SHARE
Steering Committee.J Hypertens. 2011 Aug;29(8):1633-40.
153) Cardiovascular risk and endothelial dysfunction: the preferential route for
atherosclerosis.Grassi D, Desideri G, Ferri C. Curr Pharm Biotechnol. 2011
25
Sep;12(9):1343-53.
154) Hidden sodium in Mediterranean food. Ferri C, Grassi D.J Hypertens. 2011
Oct;29(10):2041-2.
155) Aortic stiffness, blood pressure and renal dysfunction.Grassi D, Ferri C. Intern
Emerg Med. 2011 Oct;6 Suppl 1:111-4.
156) Cognitive decline as a consequence of essential hypertension.Grassi D, Ferri L,
Cheli P, Di Giosia P, Ferri C. Curr Pharm Des. 2011;17(28):3032-8.
157) The history of primary hyperaldosteronism with simultaneous hypercortisolism.
Ferri C, Grassi D. J Hypertens. 2012 Feb;30(2):432-3.
158) Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys
on hypertension.Tocci G, Rosei EA, Ambrosioni E, Borghi C, Ferri C, Ferrucci A,
Mancia G, Morganti A, Pontremoli R, Trimarco B, Zanchetti A, Volpe M. J
Hypertens. 2012 Jun;30(6):1065-74.
159) Lysine-specific demethylase 1: an epigenetic regulator of salt-sensitive
hypertension.Williams JS, Chamarthi B, Goodarzi MO, Pojoga LH, Sun B, Garza AE,
Raby BA, Adler GK, Hopkins PN, Brown NJ, Jeunemaitre X, Ferri C, Fang R,
Leonor T, Cui J, Guo X, Taylor KD, Ida Chen YD, Xiang A, Raffel LJ, Buchanan TA,
Rotter JI, Williams GH, Shi Y. Am J Hypertens. 2012 Jul;25(7):812-7.
160) The Medical and Endovascular Treatment of Atherosclerotic Renal Artery
Stenosis (METRAS) study: rationale and study design.Rossi GP, Seccia TM, Miotto
D, Zucchetta P, Cecchin D, Calò L, Puato M, Motta R, Caielli P, Vincenzi M,
Ramondo G, Taddei S, Ferri C, Letizia C, Borghi C, Morganti A, Pessina AC;
METRAS Investigators. J Hum Hypertens. 2012 Aug;26(8):507-16.
161) Different polymorphisms of the mineralocorticoid receptor gene are associated
with either glucocorticoid or mineralocorticoid levels in hypertension.Sun B,
Chamarthi B, Williams JS, Krug AW, Lasky-Su J, Raby BA, Hopkins PN,
Jeunemaitre X, Ferri C, Williams GH. J Clin Endocrinol Metab. 2012
Sep;97(9):E1825-9.
162) Protective effects of flavanol-rich dark chocolate on endothelial function and
wave reflection during acute hyperglycemia.Grassi D, Desideri G, Necozione S,
Ruggieri F, Blumberg JB, Stornello M, Ferri C. Hypertension. 2012 Sep;60(3):827-
32.
163) Benefits in cognitive function, blood pressure, and insulin resistance through
cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the
Cocoa, Cognition, and Aging (CoCoA) study.Desideri G, Kwik-Uribe C, Grassi D,
Necozione S, Ghiadoni L, Mastroiacovo D, Raffaele A, Ferri L, Bocale R, Lechiara
MC, Marini C, Ferri C. Hypertension. 2012 Sep;60(3):794-801.
164) Nonmodulation as the mechanism for salt sensitivity of blood pressure in
individuals with hypertension and type 2 diabetes mellitus.Underwood PC, Chamarthi
B, Williams JS, Vaidya A, Garg R, Adler GK, Grotzke MP, Staskus G, Wadwekar D,
Hopkins PN, Ferri C, McCall A, McClain D, Williams GH. J Clin Endocrinol Metab.
2012 Oct;97(10):3775-82.
165)[Renal denervation for the treatment of resistant hypertension: definition, patient
selection and description of the procedure. 2012 Position paper of the Italian Society
of Hypertension].Volpe M, Agabiti-Rosei E, Ambrosioni E, Cottone S, Cuspidi C,
26
Borghi C, De Luca N, Fallo F, Ferri C, Mancia G, Morganti A, Muiesan ML, Sarzani
R, Sechi L, Tocci G, Virdis A; Società Italiana dell'Ipertensione Arteriosa. G Ital
Cardiol (Rome). 2012 Dec;13(12):846-52.
166) Strategies for improving blood pressure control in Italy: from global
cardiovascular risk stratification to combination therapy. 2012 Position paper of the
Italian Society of Hypertension].Volpe M, Ambrosioni E, Borghi C, Cottone S,
Cuspidi C, De Luca N, Fallo F, Ferri C, Morganti A, Muiesan ML, Sarzani R, Sechi
L, Virdis A, Tocci G, Agabiti-Rosei E, Trimarco B, Filippi A, Mancia G; Società
Italiana dell'Ipertensione Arteriosa. G Ital Cardiol (Rome). 2012 Dec;13(12):853-60.
167) Renal artery denervation for treating resistant hypertension : definition of the
disease, patient selection and description of the procedure.Volpe M, Rosei EA,
Ambrosioni E, Cottone S, Cuspidi C, Borghi C, De Luca N, Fallo F, Ferri C, Mancia
G, Morganti A, Muiesan ML, Sarzani R, Sechi L, Tocci G, Virdis A; Italian Society
of Hypertension. High Blood Press Cardiovasc Prev. 2012 Dec;19(4):237-44.
168) Endothelium/nitric oxide mechanism mediates vasorelaxation and counteracts
vasoconstriction induced by low concentration of flavanols.Aggio A, Grassi D, Onori
E, D'Alessandro A, Masedu F, Valenti M, Ferri C. Eur J Nutr. 2013 Feb;52(1):263-
72.
169) 2012 consensus document of the Italian Society of Hypertension (SIIA):
strategies to improve blood pressure control in Italy: from global cardiovascular risk
stratification to combination therapy.Volpe M, Rosei EA, Ambrosioni E, Cottone S,
Cuspidi C, Borghi C, De Luca N, Fallo F, Ferri C, Morganti A, Muiesan ML, Sarzani
R, Sechi L, Virdis A, Tocci G, Trimarco B, Filippi A, Mancia G; Italian Society of
Hypertension. High Blood Press Cardiovasc Prev. 2013 Mar;20(1):45-52.
170) Renin-angiotensin-aldosterone system blockade is safe and effective in elderly
hypertensive patients with and without impaired renal function.Ferri C, Ferri L.High
Blood Press Cardiovasc Prev. 2012 Dec;19(4):197-8.
171) Abnormal aldosterone physiology and cardiometabolic risk factors.Vaidya A,
Underwood PC, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH, Adler GK.
Hypertension. 2013 Apr;61(4):886-93.
172) Long-term blood pressure changes induced by the 2009 L'Aquila earthquake:
assessment by 24 h ambulatory monitoring.Giorgini P, Striuli R, Petrarca M, Petrazzi
L, Pasqualetti P, Properzi G, Desideri G, Omboni S, Parati G, Ferri C. Hypertens Res.
2013 Sep;36(9):795-8.
173) Clinical management of hypertension in pregnancy. Practical recommendations
from the Italian Society of Hypertension (SIIA). [corrected].Borghi C, Ferri C, Sechi
L; Italian Society of Hypertension. High Blood Press Cardiovasc Prev. 2013
Sep;20(3):123-7.
174) Are physicians underestimating the challanges of hypertension
management?Results from the Supporting Hypertension Awareness and Research
Europe-wide (SHARE) survey. Erdine S, Redon J, Böhm M, Ferri C, Kolloch R,
Kreutz R, Laurent S, Persu A, Schmieder RE; SHARE Steering Committee. Eur J
Prev Cardiol. 2013 Oct;20(5):786-92.
175) Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated
endothelial cell dysfunction by modulating the p38/SirT1 axis. Marampon F, Gravina
GL, Scarsella L, Festuccia C, Lovat F, Ciccarelli C, Zani BM, Polidoro L, Grassi D,
Desideri G, Evangelista S, Ferri C. J Hypertens. 2013;31(10):1972-83.
27
176) Cocoa powder triggers neuroprotective and preventive effects in a human
Alzheimer's disease model by modulating BDNF signaling pathway.Cimini A, Gentile
R, D'Angelo B, Benedetti E, Cristiano L, Avantaggiati ML, Giordano A, Ferri C,
Desideri G. J Cell Biochem. 2013 Oct;114(10):2209-20.
177) Protective effects of dark chocolate on endothelial function and diabetes.Grassi
D, Desideri G, Ferri C. Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):662-8.
178) Tea, flavonoids, and cardiovascular health: endothelial protection.Grassi D,
Desideri G, Di Giosia P, De Feo M, Fellini E, Cheli P, Ferri L, Ferri C.Am J Clin
Nutr. 2013 Dec;98(6 Suppl):1660S-1666S.
179) Chronic hyperuricemia, uric acid deposit and cardiovascular risk.Grassi D, Ferri
L, Desideri G, Di Giosia P, Cheli P, Del Pinto R, Properzi G, Ferri C. Curr Pharm
Des. 2013;19(13):2432-8.
180) Hyperuricemia and cardiovascular risk.Grassi D, Desideri G, Di Giacomantonio
AV, Di Giosia P, Ferri C. High Blood Press Cardiovasc Prev. 2014 Feb 20.
181) National survey on excellence centers and reference centers for hypertension
diagnosis and treatment: geographical distribution, medical facilities and diagnostic
opportunities.Tocci G, De Luca N, Sarzani R, Ambrosioni E, Borghi C, Cottone S,
Cuspidi C, Fallo F, Ferri C, Morganti A, Muiesan ML, Sechi L, Virdis A, Mancia G,
Volpe M. High Blood Press Cardiovasc Prev. 2014 Mar;21(1):29-36.
182) New Insight into Urate-Related Mechanism of Cardiovascular Damage.Grassi D,
Desideri G, Ferri C. Curr Pharm Des. 2014 Apr 16.
183) Therapeutic Approaches to Chronic Hyperuricemia and Gout.Grassi D,
Pontremoli R, Bocale R, Ferri C, Desideri G. High Blood Press Cardiovasc Prev.
2014 Apr 3.
184) Serum uric acid levels and metabolic syndrome.Ciarla S, Struglia M, Giorgini P,
Striuli R, Necozione S, Properzi G, Ferri C. Arch Physiol Biochem. 2014 Jun 10:1-4.
185) Aldosterone dysregulation with aging predicts renal vascular function and
cardiovascular risk. Brown JM, Underwood PC, Ferri C, Hopkins PN, Williams GH,
Adler GK, Vaidya A. Hypertension. 2014 Jun;63(6):1205-11.
186) Galletti F, Agabiti-Rosei E, Bernini G, Boero R, Desideri G, Fallo F, Mallamaci
F, Morganti A, Castellano M, Nazzaro P, Trimarco B, Strazzullo P; MINISAL-GIRCSI
Program Study Group. Excess dietary sodium and inadequate potassium intake by
hypertensive patients in Italy: results of the MINISAL-SIIA study program. J
Hypertens. 2014;32(1):48-56.
187) Garza AE, Rariy CM, Sun B, Williams JS, Lasky-Su J, Baudrand R, Yao T,
Moize B, Hafiz WM, Romero JR, Adler GK, Ferri C, Hopkins PN, Pojoga LH,
Williams GH. Variants in striatin gene are associated with salt-sensitive blood pressure
in mice and humans. Hypertension. 2015;65(1):211-7.
188) Grassi D, Desideri G, Necozione S, di Giosia P, Barnabei R, Allegaert L,
Bernaert H, Ferri C. Cocoa consumption dose-dependently improves flow-mediated
dilation and arterial stiffness decreasing blood pressure in healthy individuals.
J Hypertens. 2015;33(2):294-303.
28
189) Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. Association
Between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic
Review and Meta-analysis. Inflamm Bowel Dis. 2015;21(11):2708-17.
190) Ciarla S, Giorgini P, Struglia M, Striuli R, Necozione S, Desideri G, Properzi G,
Ferri C. Associations between low levels of serum uric acid and cardiometabolic
parameters. Arch Physiol Biochem. 2015;121(4):139-43.
191) Giorgini P, Rubenfire M, Das R, Gracik T, Wang L, Morishita M, Bard RL,
Jackson EA, Fitzner CA, Ferri C, Brook RD. Particulate matter air pollution and
ambient temperature: opposing effects on blood pressure in high-risk cardiac patients.
J Hypertens. 2015;33(10):2032-8.
192) Grassi D, Desideri G, Mai F, Martella L, De Feo M, Soddu D, Fellini E, Veneri
M, Stamerra CA, Ferri C. Cocoa, glucose tolerance, and insulin signaling:
cardiometabolic protection. J Agric Food Chem. 2015;63(45):9919-26.
193) Ferri C, Desideri G, Ferri L, Proietti I, Di Agostino S, Martella L, Mai F, Di
Giosia P, Grassi D. Cocoa, blood pressure, and cardiovascular health. J Agric Food
Chem. 2015;63(45):9901-9.
194) Ghiadoni L, Bruno RM, Cartoni G, Stea F, Magagna A, Virdis A, Grassi D,
Ferri C, Taddei S. Combination therapy with lercanidipine and enalapril reduced
central blood pressure augmentation in hypertensive patients with metabolic
syndrome. Vascul Pharmacol. 2015 Jun 10.
195) Giorgini P, Rubenfire M, Das R, Gracik T, Wang L, Morishita M, Bard RL,
Jackson EA, Fitzner CA, Ferri C, Brook RD. Higher fine particulate matter and
temperature levels impair exercise capacity in cardiac patients. Heart.
2015;101(16):1293-301.
196) Giorgini P, Rubenfire M, Bard RL, Jackson EA, Ferri C, Brook RD. Air
Pollution and Exercise: a review of the cardiovascular implications for healthcare
professionals . J Cardiopulm Rehabil Prev. 2016, 36(2):84-95.
197) Martocchia A, Stefanelli M, Falaschi GM, Toussan L, Ferri C, Falaschi P.
Recent advances in the role of cortisol and metabolic syndrome in age-related
degenerative diseases. Aging Clin Exp Res. 2016;28(1):17-23.
198) Mastroiacovo D, Kwik-Uribe C, Grassi D, Necozione S, Raffaele A, Pistacchio
L, Righetti R, Bocale R, Lechiara MC, Marini C, Ferri C, Desideri G. Cocoa flavanol
consumption improves cognitive function, blood pressure control, and metabolic
profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study--a
randomized controlled trial. Am J Clin Nutr. 2015;101(3):538-48.
199) Giorgini P, Di Giosia P, Grassi D, Rubenfire M, Brook RD, Ferri C. Air
Pollution Exposure and Blood Pressure: An Updated Review of the Literature. Curr
Pharm Des. 2016;22(1):28-51.
200) Grassi D, Ferri C, Desideri G. Brain Protection and Cognitive Function: Cocoa
Flavonoids as Nutraceuticals. Curr Pharm Des. 2016;22(2):145-51.
201) Tocci G, Ferrucci A, Pontremoli R, Ferri C, Rosei EA, Morganti A, Trimarco B,
Mancia G, Borghi C, Volpe M. Blood pressure levels and control in Italy:
29
comprehensive analysis of clinical data from 2000-2005 and 2005-2011 hypertension
surveys. J Hum Hypertens. 2015;29(11):696-701.
202) Grassi D, Draijer R, Desideri G, Mulder T, Ferri C. Black tea lowers blood
pressure and wave reflections in fasted and postprandial conditions in hypertensive
patients: a randomised study. Nutrients. 2015;7(2):1037-51.
203) Ferri C. Strategies for reducing the risk of cardiovascular disease in patients with
chronic obstructive pulmonary disease. High Blood Press Cardiovasc Prev.
2015;22(2):103-11.
204) Di Giosia P, Giorgini P, Ferri C. Is labor-onset hypertension a novel category
among hypertensive disorders of pregnancy associated with adverse events in high-
risk subjects? Lights and shadows. Hypertens Res. 2016; 39(6):401-3
205) Sahebkar A, Simental-Mendía LE, Giorgini P, Ferri C, Grassi D. Lipid profile
changes after pomegranate consumption: A systematic review and meta-analysis of
randomized controlled trials. Phytomedicine. 2016; 23(11):1103-12.
206) Sahebkar A, Di Giosia P, Stamerra CA, Grassi D, Pedone C, Ferretti G,
Bacchetti T, Ferri C, Giorgini P. Effect of monoclonal antibodies to PCSK9 on high-
sensitivity C-reactive protein levels: A Meta-Analysis of 16 Randomized Controlled
Treatment Arms. Br J Clin Pharmacol. 2016; 81(6):1175-90
207) Giorgini P, Grassi D, Di Giosia P, Ferri C. Exercise training improves
cardiopulmonary and endothelial function in women with breast cancer: findings from
the Diana-5 study. Intern Emerg Med. 2016;11(2):171-3.
208) Giorgini P, Di Giosia P, Ferri L, Ferri C. Cardiovascular events in patients with
the chronic obstructive bronchopulmonary disease. J Cardiovasc Med. 2016. [Epub
ahead of print]
209) Baudrand R, Gupta N, Garza AE, Vaidya A, Leopold JA, Hopkins PN,
Jeunemaitre X, Ferri C, Romero JR, Williams J, Loscalzo J, Adler GK, Williams GH,
Pojoga LH. Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and
Lipid Homeostasis. J Am Heart Assoc. 2016;5(10).
210) Rozza F, Trimarco V, Izzo R, Grassi D, Ferri C. Effects of a Novel Fixed
Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid
Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA
Study. High Blood Press Cardiovasc Prev. 2016; 23(4):381-386
211) Sahebkar A, Giorgini P, Ludovici V, Pedone C, Ferretti G, Bacchetti T, Grassi
D, Di Giosia P, Ferri C. Impact of statin therapy on plasma resistin and visfatin
concentrations: A systematic review and meta-analysis of controlled clinical trials.
Pharmacol Res. 2016;111:827-37
212) Grassi D, Socci V, Tempesta D, Ferri C, De Gennaro L, Desideri G, Ferrara M.
Flavanol-rich chocolate acutely improves arterial function and working memory
performance counteracting the effects of sleep deprivation in healthy individuals. J
Hypertens. 2016;34(7):1298-308
213) Tocci G, Muiesan ML, Parati G, Agabiti Rosei E, Ferri C, Virdis A, Pontremoli
R, Mancia G, Borghi C, Volpe M; Working Group of the Italian Society of
30
Hypertension (SIIA) and SIIA Foundation. Trends in Prevalence, Awareness,
Treatment, and Control of Blood Pressure Recorded From 2004 to 2014 During World
Hypertension Day in Italy. J Clin Hypertens 2016;18(6):551-6.
214) Galletti F, Barbato A; MINISAL-SIIA Study Group. Prevalence and
determinants of resistant hypertension in a sample of patients followed in Italian
hypertension centers: results from the MINISAL-SIIA study program. J Hum
Hypertens. 2016;30(11):703-708.
215) Redon J, Pichler G; Missed Dose Study Group. Comparative study of the
efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood
pressure after missed dose in type 2 diabetes. J Hypertens. 2016;34(2):359-67.
216) Grassi D, Draijer R, Schalkwijk C, Desideri G, D'Angeli A, Francavilla S,
Mulder T, Ferri C. Black Tea Increases Circulating Endothelial Progenitor Cells and
Improves Flow Mediated Dilatation Counteracting Deleterious Effects from a Fat
Load in Hypertensive Patients: A Randomized Controlled Study. Nutrients. 2016
16;8(11).
217) Petrarca M, Scipioni R, Di Giosia P, Giorgini P, Ferri C. A case of brain
calcifications in postsurgical hypoparathyroidism. Intern Emerg Med. 2017;12(1):113-
115.
218) Desideri G, Gentile R, Antonosante A, Benedetti E, Grassi D, Cristiano L,
Manocchio A, Selli S, Ippoliti R, Ferri C, Borghi C, Giordano A, Cimini A. Uric Acid
Amplifies Aβ Amyloid Effects Involved in the Cognitive Dysfunction/Dementia:
Evidences From an Experimental Model In Vitro. J Cell Physiol. 2017; 232(5):1069-
1078
219) Giorgini P, Di Giosia P, Ferri L, Ferri C. Cardiovascular events in patients with
chronic obstructive bronchopulmonary disease. J Cardiovasc Med 2017; 18 Suppl
1:e23-e29.
220) Sahebkar A, Ferri C, Giorgini P, Bo S, Nachtigal P, Grassi D. Effects of
pomegranate juice on blood pressure: A systematic review and meta-analysis of
randomized controlled trials. Pharmacol Res. 2017;115:149-161.
221) Giorgini P, Sahebkar A, Stamerra CA, Raparelli V, Petrarca M, Grassi D, Ferri
C, Di Giosia P. Comparison of Clinical Outcomes Between Genders Following
Antihypertensive Therapy: A Meta-Analysis. Curr Med Chem. 2017;24(24):2639-
2649.
222) Ferri C, Ferri L, Desideri G. Management of Hypertension in the Elderly and
Frail Elderly. High Blood Press Cardiovasc Prev. 2017;24(1):1-11.
223) Giorgini P, Di Giosia P, Petrarca M, Lattanzio F, Stamerra CA, Ferri C. Climate
Changes and Human Health: A Review of the Effect of Environmental Stressors on
Cardiovascular Diseases Across Epidemiology and Biological Mechanisms. Curr
Pharm Des. 2017;23(22):3247-3261.
224) Maiolino G, Rossitto G, Bisogni V, Cesari M, Seccia TM, Plebani M, Rossi GP;
PAPY Study Investigators.Quantitative Value of Aldosterone-Renin Ratio for
Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for
Primary Aldosteronism (AQUARR) Study. J Am Heart Assoc. 2017;21;6(5).
31
225) Cardiovascular risk and hypertension control in Italy. Data from the 2015 World
Hypertension Day. Torlasco C, Faini A, Makil E, Ferri C, Borghi C, Veglio F,
Desideri G, Agabiti Rosei E, Ghiadoni L, Pauletto P, Pontremoli R, Stornello M,
Tocci G, Galletti F, Trimarco B, Parati G; Council of the Italian Society of
Hypertension. Int J Cardiol. 2017;243:529-532.
226) Ludovici V, Barthelmes J, Nägele MP, Enseleit F, Ferri C, Flammer AJ,
Ruschitzka F, Sudano I.Cocoa, Blood Pressure, and Vascular Function. Front Nutr.
2017;4:36.
227) Ferri C. The problem of cardio-renal diseases in patients with gout. Curr Med
Res Opin. 2017;33(sup3):9-13.
228) Castelli V, Grassi D, Bocale R, d'Angelo M, Antonosante A, Cimini A, Ferri C,
Desideri G. Diet and Brain Health: Which Role for Polyphenols? Curr Pharm Des.
2017 Dec 12.
229) Stamerra CA, Di Giosia P, Giorgini P, De Feo M, Grassi D, Ferri C, Sahebkar
A. Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the
evidence. J Neurosci Res. J Neurosci Res. 2018;96(5):762-764.
230) Cervelli N, Tocci G, Ferri C. Proprotein Convertase Subtilisin-Kexin Type 9
(PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier
Trial Suggest Changes in the Target of Lipid Lowering Therapy? High Blood Press
Cardiovasc Prev. 2018 Jan 5.
231) Ferri C. Diuretics (chapter). Encyclopedia of Endocrine Diseases, 2nd Edition.
MRW - Elsevier Limited. In press.
232) Pietropaoli D, Del Pinto R, Ferri C, Wright JT Jr, Giannoni M, Ortu E, Monaco
A. Poor Oral Health and Blood Pressure Control Among US Hypertensive Adults:
Results From the National Health and Nutrition Examination Survey 2009 to 2014
Hypertension. 2018;72(6):1365-1373
233) Duro G, Zizzo C, Cammarata G, Burlina A, Burlina A, Polo G, Scalia S, Oliveri
R, Sciarrino S, Francofonte D, Alessandro R, Pisani A, Palladino G, Napoletano R,
Tenuta M, Masarone D, Limongelli G, Riccio E, Frustaci A, Chimenti C, Ferri C,
Pieruzzi F, Pieroni M, Spada M, Castana C, Caserta M, Monte I, Rodolico MS,
Feriozzi S, Battaglia Y, Amico L, Losi MA, Autore C, Lombardi M, Zoccali C, Testa
A, Postorino M, Mignani R, Zachara E, Giordano A, Colomba P.
Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease? Int J
Mol Sci. 2018 Nov 23;19(12).
234) Del Pinto R, Ferri C. Inflammation-Accelerated Senescence and the
Cardiovascular System: Mechanisms and Perspectives. Int J Mol Sci. 2018;19(12).
235) Del Pinto R, Ferri C. Hypertension Management at Older Age: An Update. High
Blood Press Cardiovasc Prev. 2018 Nov 22.
236) Bringhen S, Milan A, Ferri C, Wäsch R, Gay F, Larocca A, Salvini M, Terpos E,
Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M,
Boccadoro M, Einsele H, Sonneveld P, Engelhardt M; European Hematology
Association, the European Myeloma Network and the Italian Society of Arterial
Hypertension. Cardiovascular adverse events in modern myeloma therapy - Incidence
and risks. A review from the European Myeloma Network (EMN) and Italian Society
of Arterial Hypertension (SIIA). Haematologica. 2018;103(9):1422-1432.
32
237) Crosta F, Occhiuzzi U, Passalacqua G, Occhiuzzi E, Cimini A, Grassi D, Ferri
C, Marini C, Borghi C, Desideri G. Association Between the Serum Uric Acid Levels
and Lacunar Infarcts in the Elderly. J Mol Neurosci. 2018;65(3):385-390.
238) Del Pinto R, Ferri C, Borghi C. Letter Regarding Article, "Prevention of Stroke
With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary
Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy
International Trial)". Circulation. 2018;137(24):2654-2655.
239) Del Pinto R, Pietropaoli D, Ferri C. Diastolic blood pressure and risk profile in
renal and cardiovascular diseases. Results from the SPRINT trial. J Am Soc
Hypertens. 2018;12(7):513-523.e3.
240) Del Pinto R, Pietropaoli D, Russomando U, Evangelista P, Ferri C. Health status
of Afro-Asian refugees in an Italian urban area: a cross-sectional monocentric study.
Public Health. 2018;158:176-182.
241) Di Giosia P, Giorgini P, Ferri C. Considerations on stroke in atrial fibrillation
despite anticoagulation. J Cardiovasc Med (Hagerstown). 2018;19 Suppl 1:e54-e57.
doi: 10.2459/JCM.0000000000000602. No abstract available.
242) Di Giosia P, Giorgini P, Stamerra CA, Petrarca M, Ferri C, Sahebkar AGender
Differences in Epidemiology, Pathophysiology, and Treatment of Hypertension. Curr
Atheroscler Rep. 2018;20(3):13.
243) Desideri G, Virdis A, Casiglia E, Borghi C; Working Group on Uric Acid and
Cardiovascular Risk of the Italian Society of Hypertension. Exploration into Uric and
Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study
Protocol for a Retrospective Observational Study. High Blood Press Cardiovasc Prev.
2018;25(2):197-202.
244) Del Pinto R, Ferri C. Inflammation-Accelerated Senescence and the
Cardiovascular System: Mechanisms and Perspectives. Int J Mol Sci. 2018;19(12).
245) Del Pinto R, Ferri C. Hypertension Management at Older Age: An Update. High
Blood Press Cardiovasc Prev. 2019 Feb;26(1):27-36. doi: 10.1007/s40292-018-0290-
z. Epub 2018 Nov 22.
246) Pietropaoli D, Del Pinto R, Ferri C, Wright JT Jr, Giannoni M, Ortu E, Monaco
A. Poor Oral Health and Blood Pressure Control Among US Hypertensive Adults:
Results From the National Health and Nutrition Examination Survey 2009 to 2014
Hypertension. 2018;72(6):1365-1373.
247) Duro G, Zizzo C, Cammarata G, Burlina A, Burlina A, Polo G, Scalia S, Oliveri
R, Sciarrino S, Francofonte D, Alessandro R, Pisani A, Palladino G, Napoletano R,
Tenuta M, Masarone D, Limongelli G, Riccio E, Frustaci A, Chimenti C, Ferri C,
Pieruzzi F, Pieroni M, Spada M, Castana C, Caserta M, Monte I, Rodolico MS,
Feriozzi S, Battaglia Y, Amico L, Losi MA, Autore C, Lombardi M, Zoccali C, Testa
A, Postorino M, Mignani R, Zachara E, Giordano A, Colomba P. Mutations in the
GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease? Int J Mol Sci.
2018;19(12).
248) Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A,
Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C,
Auner H, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H,
Sonneveld P, Engelhardt M. Prevention, monitoring and treatment of cardiovascular
33
adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the
European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern
Med. 2019 Feb 6.
249) Cicero AFG, Grassi D, Tocci G, Galletti F, Borghi C, Ferri C. Nutrients and
Nutraceuticals for the Management of High Normal Blood Pressure: An Evidence-
Based Consensus Document. High Blood Press Cardiovasc Prev. 2019;26(1):9-25.
250) Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C. Low Density Lipoprotein
(LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of
PCSK9 Inhibitors. High Blood Press Cardiovasc Prev. 2019;26(3):199-207.
251) Del Pinto R, Pagliacci S, De Feo M, Grassi D, Ferri C; Italian Society of
Hypertension and Federfarma. Prevalence of hypertension and associated
cardiovascular risk factors among pharmacies customers: an Italian nationwide
epidemiological survey. Eur J Prev Cardiol. 2019 May 22:2047487319851301.
252) Pietropaoli D, Del Pinto R, Ferri C, Ortu E, Monaco A. Definition of
hypertension-associated oral pathogens in NHANES. J Periodontol. 2019 May 15.
253) Is circulating endothelin evaluation useful for clinicians? Ferri C, Desideri G.
Intern Emerg Med. 2019 May 10.
254) Torlasco C, Faini A, Makil E, Bilo G, Pengo M, Beaney T, Xia X, Borghi C,
Poulter NR, Tocci G, Galletti F, Desideri G, Veglio F, Ferri C, Parati G.
Nation-wide hypertension screening in Italy: data from May Measurements Month
2017-Europe. Eur Heart J Suppl. 2019;21(Suppl D):D66-D70.
255) Desideri G, Ferri C. Aspirin for primary prevention in elderly hypertensive
patients: to treat or not to treat? J Hypertens. 2019;37(6):1154-1156.